Emergent BioSolutions (EBS) Net Margin Growth (1y) (2012 - 2026)

Emergent BioSolutions (EBS) Net Margin Growth (1y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin Growth (1y) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 364.00
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -82.00
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -4,395.00
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -538.00
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 9,850.00
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 2,292.00
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -146.00
10 Emergent BioSolutions 389.77 Mn 228.27 Mn 84.10 Mn -2,625.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -2,625.00
Dec 31, 2025 -2,064.00
Sep 30, 2025 -1,692.00
Jun 30, 2025 55,768.00
Mar 31, 2025 2,761.00
Dec 31, 2024 182.00
Sep 30, 2024 13,645.00
Jun 30, 2024 -48,884.00
Mar 31, 2024 11,633.00
Dec 31, 2023 239.00
Sep 30, 2023 -6,107.00
Jun 30, 2023 -5,411.00
Mar 31, 2023 -11,212.00
Dec 31, 2022 -4,456.00
Sep 30, 2022 -2,489.00
Jun 30, 2022 -2,447.00
Mar 31, 2022 -1,970.00
Dec 31, 2021 -765.00
Sep 30, 2021 -2,168.00
Jun 30, 2021 -2,227.00